GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Protalix BioTherapeutics Inc (FRA:PBDA) » Definitions » Repurchase of Stock

Protalix BioTherapeutics (FRA:PBDA) Repurchase of Stock : €0.00 Mil (TTM As of Mar. 2025)


View and export this data going back to 2008. Start your Free Trial

What is Protalix BioTherapeutics Repurchase of Stock?

Protalix BioTherapeutics's Repurchase of Stock for the three months ended in Mar. 2025 was €0.00 Mil.

Protalix BioTherapeutics's Repurchase of Stock for the trailing twelve months (TTM) ended in Mar. 2025 was €0.00 Mil.


Protalix BioTherapeutics Repurchase of Stock Historical Data

The historical data trend for Protalix BioTherapeutics's Repurchase of Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Protalix BioTherapeutics Repurchase of Stock Chart

Protalix BioTherapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Repurchase of Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Protalix BioTherapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Repurchase of Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Protalix BioTherapeutics Repurchase of Stock Calculation

A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of Stock represents the cash outflow to reacquire common stock during the period.

Repurchase of Stock for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Protalix BioTherapeutics Repurchase of Stock Related Terms

Thank you for viewing the detailed overview of Protalix BioTherapeutics's Repurchase of Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Protalix BioTherapeutics Business Description

Traded in Other Exchanges
Address
2 University Plaza, Suite 100, Hackensack, NJ, USA, 07601
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

Protalix BioTherapeutics Headlines

No Headlines